GenomeKey and Oxford Nanopore Technologies collaborate

GenomeKey and Oxford Nanopore Technologies collaborate

GenomeKey and Oxford Nanopore Technologies collaborate to develop a new diagnostic tool for bloodstream infections

GenomeKey and Oxford Nanopore Technologies have announced a collaboration to develop a new diagnostic tool for bloodstream infections that has the potential to be transformative in the battle against sepsis.

“GenomeKey is excited to join forces with Oxford Nanopore, whose innovative sequencing technology enhances our cutting-edge diagnostic device,” said Dr Michael Roberts, CEO of GenomeKey.  “This collaboration is set to transform how we manage and treat sepsis, offering clinicians rapid and accurate results that can save lives. Together, we are setting new standards in healthcare, enabling quicker and more precise medical interventions.”

An ideal collaborator for GenomeKey’s automated bench-top device, Oxford Nanopore Technologies’ sequencing technology can analyse native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths. The rich, real-time data generated by Oxford Nanopore’s platform gives lab clinicians the power to rapidly detect, identify and evaluate antimicrobial susceptibility in as little as hours rather than days.

“Sepsis is a major healthcare crisis that is impacting up to 50 million people annually, resulting in 11 million deaths worldwide,” said Emma Stanton, Oxford Nanopore’s SVP, Clinical. “Through the provision of rapid and accurate diagnostics, GenomeKey has the potential to turn the tables on sepsis, delivering fast treatment for those in need. We are proud that Oxford Nanopore’s platform technology will play a critical role in GenomeKey’s journey.”

As part of the collaboration, GenomeKey will receive continued support and access to the latest technologies emerging from Oxford Nanopore.

About GenomeKey

GenomeKey is an award-winning, UK biotechnology company utilising cutting-edge AI machine learning to address critical healthcare challenges. The company is developing an in vitro diagnostic device to dramatically reduce the time to identify the right antibiotic for serious infections, such as sepsis. This low-cost device will save lives, save money and help to reduce the risk of emerging bacterial drug resistance.
X (formerly Twitter)

About Oxford Nanopore Technologies

Oxford Nanopore Technologies’ goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for real-time, high-performance, accessible and scalable analysis of DNA and RNA. The technology is used in more than 120 countries to understand the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses, and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes.

For more, visit: